Among U.S. adults with diabetes from 1988 to 2014, the overall prevalence of diabetic kidney disease did not change significantly, while the prevalence of albuminuria declined and the prevalence of reduced estimated glomerular filtration rate increased, according to a study appearing in the August 9 issue of JAMA.
Diabetes mellitus is the most common cause of chronic kidney disease in the world, leading to multiple complications including end-stage renal disease, cardiovascular disease, infection, and death. Chronic kidney disease in the setting of diabetes or diabetic kidney disease (DKD), manifests clinically as albuminuria (the presence of excessive protein in the urine), reduced glomerular filtration rate (GFR; a measure of kidney function), or both. Changes in demographics and treatments may affect the prevalence and clinical manifestations of diabetic kidney disease.
Ian H. de Boer, M.D., M.S., of the University of Washington, Seattle, and colleagues analyzed data of 6,251 adults with diabetes mellitus participating in National Health and Nutrition Examination Surveys from 1988 through 2014.
The researchers found that the prevalence of any diabetic kidney disease, defined as persistent albuminuria, persistent reduced estimated (e) GFR, or both, did not significantly change over time from 28 percent in 1988-1994 to 26 percent in 2009-2014. However, the prevalence of albuminuria decreased progressively over time from 21 percent in 1988-1994 to 16 percent in 2009-2014. In contrast, the prevalence of reduced eGFR increased from 9 percent in 1988-1994 to 14 percent in 2009-2014, with a similar pattern for severely reduced eGFR.
Significant heterogeneity in the trend for albuminuria was noted by age and race/ethnicity, with a decreasing prevalence of albuminuria observed only among adults younger than 65 years and non-Hispanic whites, whereas the prevalence of reduced GFR increased without significant differences by age or race/ethnicity. In 2009-2014, approximately 8.2 million adults with diabetes had albuminuria, reduced eGFR, or both.
The authors write that the lower prevalence of albuminuria observed over time may be attributable to a higher rate of prescribed diabetes therapies (glucose-lowering medications, renin-angiotensin-aldosterone system [RAAS] inhibitors, and statins). And that while reasons for the increasing prevalence of reduced eGFR cannot be conclusively discerned from these data, it is possible that hemodynamic effects of RAAS inhibitors and improved blood pressure control could contribute to lower eGFR. Alternatively, an increasing duration of diabetes may be contributing to kidney damage.
(doi:10.1001/jama.2016.10924; the study is available pre-embargo to the media at the For the Media website)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact Ian H. de Boer, M.D., M.S., call Bobbi Nodell at 206-543-7129 or email email@example.com.
To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jama.